Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate
Imagion Biosystems has announced a Secondary Supplementary Prospectus. Read the Secondary Supplementary Prospectus.
Imagion Biosystems has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.
The securities of Imagion Biosystems Limited (‘IBX’) will be placed in a trading halt at the request of IBX, pending it releasing an announcement. Unless
Imagion Biosystems Limited is pleased to advise that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million.
A supplementary prospectus has been lodged with the Australian Securities and Investments Commission. This supplementary prospectus is intended to be read with the prospectus dates
Imagion Biosystems has today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 31 March 2020. Read the
Imagion Biosystems has announced receipt of its 2019 R&D tax incentive claim of A$2,197,028 from the Australian Tax Office (ATO). In May 2019 the Company
Imagion Biosystems Limited (ASX:IBX) is pleased to confirm that the rights the subject of the Company’s Renounceable Rights Issue announced on Wednesday, 25 March 2020,
Imagion Biosystems Limited has accepted the resignation of non-executive director Bronwyn Le Grice. Ms Le Grice’s resignation is effective March 31st, 2020. Read Imagion Biosystems
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance